Filters

Term Search
You can select from the dropdown list OR enter your own terms to refine the search.

Last Updated: 10/31/2025

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 353 publications

Visual Hallucinations in Serotonergic Psychedelics and Lewy Body Diseases.

Visual Hallucinations in Serotonergic Psychedelics and Lewy Body Diseases.

Journal: Schizophrenia bulletin
Published: October 06, 2025

Posttraumatic Stress Disorder Psychopharmacology Algorithm Update-2024-2025.

Posttraumatic Stress Disorder Psychopharmacology Algorithm Update-2024-2025.

Journal: Psychiatry and clinical psychopharmacology
Published: August 29, 2025

Pimavanserin safety in adult and elderly patients with neuropsychiatric symptoms related to neurodegenerative disease: An open-label extension study.

Pimavanserin safety in adult and elderly patients with neuropsychiatric symptoms related to neurodegenerative disease: An open-label extension study.

Journal: Journal of Alzheimer's disease : JAD
Published: June 16, 2025

Recommendations for management and future investigation of psychosis in neurodegenerative disease: Findings from the International Psychogeriatric Association (IPA) working group.

Recommendations for management and future investigation of psychosis in neurodegenerative disease: Findings from the International Psychogeriatric Association (IPA) working group.

Journal: International psychogeriatrics
Published: May 23, 2025

5-HT 2A receptor inverse agonist attenuates morphine withdrawal syndrome and its aversiveness in rats.

5-HT 2A receptor inverse agonist attenuates morphine withdrawal syndrome and its aversiveness in rats.

Journal: Behavioural pharmacology
Published: May 20, 2025

Pimavanserin -induced decreased appetite and weight loss: A case report.

Pimavanserin -induced decreased appetite and weight loss: A case report.

Journal: Indian journal of psychiatry
Published: May 09, 2025

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Pimavanserin as an Adjunctive Treatment for the Negative Symptoms of Schizophrenia (ADVANCE-2) in Patients With Predominant Negative Symptoms.

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Pimavanserin as an Adjunctive Treatment for the Negative Symptoms of Schizophrenia (ADVANCE-2) in Patients With Predominant Negative Symptoms.

Journal: Schizophrenia bulletin
Published: April 04, 2025

Healthcare resource utilization patterns among patients with Parkinson's disease psychosis and dementia: analysis of US Medicare beneficiaries treated with pimavanserin versus other-atypical antipsychotics or versus quetiapine.

Healthcare resource utilization patterns among patients with Parkinson's disease psychosis and dementia: analysis of US Medicare beneficiaries treated with pimavanserin versus other-atypical antipsychotics or versus quetiapine.

Journal: Journal of medical economics
Published: April 01, 2025

Management of Parkinson's disease psychosis: first-line antipsychotic selection and rationale for continuing, combining, or switching.

Management of Parkinson's disease psychosis: first-line antipsychotic selection and rationale for continuing, combining, or switching.

Journal: Expert opinion on pharmacotherapy
Published: March 26, 2025

Synthesis and evaluation of novel 5-HT2A receptor inverse agonist with excellent in vivo antipsychotic efficacy and superior tissue distribution for treatment of Parkinson's disease psychosis.

Synthesis and evaluation of novel 5-HT2A receptor inverse agonist with excellent in vivo antipsychotic efficacy and superior tissue distribution for treatment of Parkinson's disease psychosis.

Journal: European journal of medicinal chemistry
Published: March 11, 2025

Evaluation of Mortality in Users of Pimavanserin Compared with Other Atypical Antipsychotics in Patients with Parkinson's Disease Psychosis: An Update.

Evaluation of Mortality in Users of Pimavanserin Compared with Other Atypical Antipsychotics in Patients with Parkinson's Disease Psychosis: An Update.

Journal: Drug safety
Published: March 11, 2025

Sedation and sleep safety of pimavanserin for Parkinsons's disease psychosis: Review and exploratory analysis of clinical study data.

Sedation and sleep safety of pimavanserin for Parkinsons's disease psychosis: Review and exploratory analysis of clinical study data.

Journal: Clinical parkinsonism & related disorders
Published: February 20, 2025
Showing 1-12 of 353

Last Updated: 10/31/2025